Janux Therapeutics Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Janux Therapeutics Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cash flows from operating activities | ||||||||||||||||
| net income | -33,858,000 | -23,508,000 | -20,216,000 | -28,059,000 | -5,959,000 | -14,760,000 | -11,758,000 | -11,568,000 | -17,508,000 | -17,459,000 | -16,065,000 | -16,696,000 | -16,888,000 | -13,410,000 | -13,416,000 | -10,766,000 |
| adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||
| depreciation | 541,000 | 519,000 | 512,000 | 510,000 | 506,000 | 532,000 | 531,000 | 500,000 | 471,000 | 453,000 | 403,000 | 249,000 | 108,000 | 81,000 | 64,000 | 27,000 |
| stock-based compensation | 10,960,000 | 10,702,000 | 6,251,000 | 15,387,000 | 5,757,000 | 5,625,000 | 4,483,000 | 4,548,000 | 5,501,000 | 5,473,000 | 4,205,000 | 4,596,000 | 4,444,000 | 3,958,000 | 2,944,000 | 2,566,000 |
| accretion of discounts on investments | -5,206,000 | -4,221,000 | -2,927,000 | -2,898,000 | -2,973,000 | -1,787,000 | -2,061,000 | -2,108,000 | -1,841,000 | -1,678,000 | ||||||
| changes in operating assets and liabilities: | ||||||||||||||||
| accounts receivable | -6,981,000 | -519,000 | -750,000 | 0 | 375,000 | |||||||||||
| prepaid expenses and other current assets | -349,000 | -700,000 | -203,000 | -144,000 | -1,762,000 | -1,171,000 | 270,000 | 530,000 | -2,239,000 | 1,649,000 | -81,000 | -1,301,000 | -587,000 | -1,400,000 | 27,000 | -43,000 |
| other long-term assets | 99,000 | 92,000 | -61,000 | -183,000 | -116,000 | -15,000 | -195,000 | 119,000 | -822,000 | -221,000 | -313,000 | -1,142,000 | 130,000 | 55,000 | -252,000 | |
| accounts payable | 1,113,000 | -1,637,000 | 1,559,000 | 1,175,000 | -694,000 | -456,000 | 327,000 | 228,000 | -171,000 | -107,000 | 223,000 | -634,000 | 857,000 | -740,000 | -482,000 | 2,584,000 |
| accrued expenses | 2,893,000 | 1,734,000 | -1,634,000 | 4,573,000 | 3,060,000 | -1,573,000 | 426,000 | -1,987,000 | 1,443,000 | -560,000 | 1,005,000 | 2,887,000 | -894,000 | 1,158,000 | 1,921,000 | 409,000 |
| deferred revenue | 0 | -94,000 | -878,000 | -733,000 | -1,943,000 | -1,999,000 | -682,000 | -1,298,000 | -2,095,000 | -938,000 | 6,011,000 | -1,214,000 | -1,241,000 | -784,000 | ||
| operating lease right-of-use assets and liabilities | -6,000 | -5,000 | -6,000 | 2,000 | 19,000 | 20,000 | 19,000 | 28,000 | 44,000 | 587,000 | 1,597,000 | 833,000 | 845,000 | 14,000 | 12,000 | |
| net cash from operating activities | -23,813,000 | -17,024,000 | -16,725,000 | -2,231,000 | -10,021,000 | -14,837,000 | -9,901,000 | -11,709,000 | -15,054,000 | -13,911,000 | -11,913,000 | -13,414,000 | -6,073,000 | -11,522,000 | -10,481,000 | -5,854,000 |
| capex | -473,000 | -371,000 | -42,000 | -25,000 | -95,000 | -197,000 | -515,000 | -470,000 | -580,000 | -285,000 | -2,056,000 | -2,520,000 | -898,000 | -971,000 | -1,173,000 | -77,000 |
| free cash flows | -24,286,000 | -17,395,000 | -16,767,000 | -2,256,000 | -10,116,000 | -15,034,000 | -10,416,000 | -12,179,000 | -15,634,000 | -14,196,000 | -13,969,000 | -15,934,000 | -6,971,000 | -12,493,000 | -11,654,000 | -5,931,000 |
| cash flows from investing activities | ||||||||||||||||
| purchases of property and equipment | -473,000 | -371,000 | -42,000 | -25,000 | -95,000 | -197,000 | -515,000 | -470,000 | -580,000 | -285,000 | -2,056,000 | -2,520,000 | -898,000 | -971,000 | -1,173,000 | -77,000 |
| purchases of short-term investments | -92,685,000 | -371,291,000 | -24,032,000 | -32,466,000 | -235,540,000 | -178,539,000 | -33,112,000 | -135,981,000 | -76,546,000 | -71,705,000 | -86,048,000 | -94,467,000 | -68,813,000 | -45,061,000 | -103,501,000 | -227,607,000 |
| maturities of short-term investments | 94,720,000 | 31,270,000 | 58,000,000 | 45,165,000 | 44,750,000 | 65,000,000 | 44,750,000 | 75,000,000 | 95,000,000 | 63,250,000 | 86,500,000 | 116,750,000 | 78,750,000 | 77,100,000 | 112,000,000 | |
| net cash from investing activities | 1,562,000 | -340,392,000 | 33,926,000 | 12,674,000 | -190,885,000 | -113,736,000 | 11,123,000 | -61,451,000 | 17,874,000 | -8,740,000 | -1,604,000 | 19,763,000 | 9,039,000 | 31,068,000 | 7,326,000 | -205,539,000 |
| cash flows from financing activities | ||||||||||||||||
| proceeds from exercise of common stock options and employee stock purchase plan | 8,442,000 | 1,649,000 | 831,000 | |||||||||||||
| proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | 0 | -347,000 | 378,208,000 | 0 | -455,000 | 320,514,000 | 0 | |||||||||
| net cash from financing activities | 954,000 | 554,000 | 386,650,000 | 1,649,000 | 2,765,000 | 322,171,000 | 831,000 | 56,609,000 | 528,000 | 1,580,000 | 191,000 | 0 | 308,000 | 1,000 | 164,000 | -843,000 |
| net decrease in cash, cash equivalents and restricted cash | ||||||||||||||||
| cash, cash equivalents and restricted cash – beginning of year | 0 | 431,421,000 | 0 | 0 | 0 | 20,021,000 | 0 | 0 | 0 | 52,242,000 | 0 | 0 | 0 | 36,398,000 | ||
| cash, cash equivalents and restricted cash – end of period | -21,297,000 | 74,559,000 | 403,851,000 | 12,092,000 | -198,141,000 | 213,619,000 | 2,053,000 | -16,551,000 | 3,348,000 | 31,171,000 | ||||||
| supplemental disclosure of noncash investing and financing activities | ||||||||||||||||
| unpaid property and equipment | -190,000 | 237,000 | -36,000 | -298,000 | -30,000 | 65,000 | 395,000 | -1,080,000 | 726,000 | |||||||
| unrealized gain on available-for-sale securities | -9,000 | 1,593,000 | -5,668,000 | 9,447,000 | -1,092,000 | -1,189,000 | 1,840,000 | -115,000 | -321,000 | 796,000 | -370,000 | |||||
| proceeds from exercise of common stock options | 901,000 | 1,657,000 | ||||||||||||||
| net increase in cash, cash equivalents and restricted cash | -356,862,000 | 403,851,000 | 193,598,000 | 2,053,000 | -16,551,000 | 3,348,000 | -21,071,000 | -13,326,000 | 6,349,000 | 3,274,000 | 19,547,000 | |||||
| unpaid issuance costs | ||||||||||||||||
| vesting of restricted common stock | 7,000 | 3,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 134,000 | 154,000 | 169,000 | 208,000 | 503,000 | 149,000 | 148,000 | ||
| operating lease liabilities arising from right-of-use assets | 344,000 | 0 | 0 | |||||||||||||
| unpaid equity issuance costs | 438,000 | -843,000 | ||||||||||||||
| proceeds from exercise of vested and unvested common stock options and employee stock purchase plan | 528,000 | 1,580,000 | 191,000 | 0 | 308,000 | 1,000 | ||||||||||
| loss on disposal of assets | 0 | 0 | ||||||||||||||
| amortization (accretion) of premiums/discounts on investments | -1,292,000 | -768,000 | -99,000 | -24,000 | -58,000 | -79,000 | ||||||||||
| proceeds from issuance of series a convertible preferred stock, net of issuance costs | 0 | 0 | ||||||||||||||
| proceeds from issuance of series b convertible preferred stock, net of issuance costs | 0 | 0 | ||||||||||||||
| proceeds from initial public offering, net of issuance costs | 0 | -843,000 | ||||||||||||||
| cash, cash equivalents and restricted cash – end of year | 3,274,000 | 55,945,000 | ||||||||||||||
| conversion of convertible preferred stock in connection with initial public offering | 0 | 0 | ||||||||||||||
| unrealized loss on available-for-sale securities | ||||||||||||||||
| payment of initial public offering costs | ||||||||||||||||
| unpaid fixed asset additions | 396,000 | -815,000 | ||||||||||||||
| unrealized loss on short-term investments | -1,297,000 | |||||||||||||||
| noncash interest – related parties | ||||||||||||||||
| increase in fair value of convertible promissory notes – related parties | ||||||||||||||||
| proceeds from issuance of convertible promissory notes | ||||||||||||||||
| proceeds from issuance of series seed 2 convertible preferred stock, net of issuance costs | ||||||||||||||||
| conversion of convertible promissory notes and accrued interest into shares of convertible preferred stock | ||||||||||||||||
| unrealized gain on short-term investments | -294,000 | 7,000 | ||||||||||||||
| proceeds from exercise of vested and unvested common stock options | 0 | |||||||||||||||
| net increase in cash and cash equivalents | -212,236,000 | |||||||||||||||
| cash and cash equivalents – beginning of period | 0 | |||||||||||||||
| cash and cash equivalents – end of period | -212,236,000 |
We provide you with 20 years of cash flow statements for Janux Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Janux Therapeutics stock. Explore the full financial landscape of Janux Therapeutics stock with our expertly curated income statements.
The information provided in this report about Janux Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.